SCHEMBL17024448

SCHEMBL17024448

O=C(O)C1CCC(O)CN1C(=O)OCc1ccccc1.O=C(O)C1CCC(O)CN1C(=O)OCc1ccccc1.O=C(O)[C@@H]1CC[C@@H](O)CN1C(=O)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
PREP P48147 3/20 0.49
CYP2C19 P33261 1/20 0.47
AGTR2 P50052 3/20 0.47
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
KLK7 P49862 1/20 0.45
KLK5 Q9Y337 1/20 0.45
HTR2C P28335 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16857280 1.00 POLB (0.53) POLBSMN1; SMN2NPC1RAB9APREP
SCHEMBL9175610 1.00 POLB (0.53) POLBSMN1; SMN2NPC1RAB9APREP
SCHEMBL9175619 1.00 POLB (0.53) POLBSMN1; SMN2NPC1RAB9APREP
SCHEMBL9175614 1.00 POLB (0.53) POLBSMN1; SMN2NPC1RAB9APREP
SCHEMBL17024445 1.00 POLB (0.53) POLBSMN1; SMN2NPC1RAB9APREP
SCHEMBL16857358 1.00 POLB (0.53) POLBSMN1; SMN2NPC1RAB9APREP
SCHEMBL16857378 1.00 POLB (0.53) POLBSMN1; SMN2NPC1RAB9APREP
SCHEMBL9960832 1.00 POLB (0.53) POLBSMN1; SMN2NPC1RAB9APREP
SCHEMBL16857500 0.96 POLB (0.53) POLBSMN1; SMN2NPC1RAB9APREP
SCHEMBL16857515 0.91 POLB (0.52) POLBSMN1; SMN2NPC1RAB9APREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889288-B1 METHOD FOR PRODUCING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID DERIVATIVE, AND METHOD FOR PURIFYING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID API CORP (JP) 2018-07-25 EP disclosed
US-9981984-B2 Method for producing cis-5-hydroxy-2-piperidinecarboxylic acid derivative, and method for purifying cis-5-hydroxy-2-piperidinecarboxylic acid API CORPORATION (JP) 2018-05-29 US disclosed
US-20150239906-A1 Method for Producing cis-5-hydroxy-2-piperidinecarboxylic Acid Derivative, and Method for Purifying cis-5-hydroxy-2-piperidinecarboxylic Acid UBE CORPORATION (JP) 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150239906-A1 Method for Producing cis-5-hydroxy-2-piperidinecarboxylic Acid Derivative, and Method for Purifying cis-5-hydroxy-2-piperidinecarboxylic Acid HCAR2, HCAR1, C5 POLB 3432/4885SMN1; SMN2 3680/4885NPC1 3080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.